This infographic highlights 8 manufacturing challenges that are commonly experienced and 8 Exact JobBOSS Solutions to help you win more deals, ship on time and make more money. This infographic ...

Upon completion, Exact Sciences will operate as Abbott’s subsidiary. Credit: Michael Vi/Shutterstock.com. Abbott has signed a definitive agreement to acquire all of Exact Sciences’ outstanding shares ...

Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer. Under the terms of the deal, Exact Sciences' stockholders would receive $105 per share in cash. The ...

Abbott Laboratories ABT0.26%increase; green up pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS 0.43%increase; green up pointing triangle in a deal valued at about ...

Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...

Shares of Exact Sciences (EXAS) continued to rise in the premarket on Thursday, adding ~18% after the cancer test maker agreed to be acquired by Abbott Laboratories (ABT) in an all-cash deal worth ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. Abbott said Thursday it would buy Exact Sciences, the maker of tests ...

Abbott announced Thursday morning that it is acquiring Exact Sciences for $21 billion. The deal values Exact Sciences at $105 per share, representing a 22% premium to the cancer screening company’s ...

Abbott (NYSE: ABT) + announced today that it agreed to acquire diagnostics maker Exact Sciences (Nasdaq:EXAS) for approximately $21 billion. Confirmation of the deal comes just one day after reports ...

Abbott has agreed to acquire cancer test-maker Exact Sciences for about $21 billion. Exact Sciences makes the Cologuard noninvasive screening test for colorectal cancer. The company also makes tests ...